Germline
Chinese
RAD51C
RAD51D
germline mutation
hereditary breast and ovarian cancers
Journal
Journal of personalized medicine
ISSN: 2075-4426
Titre abrégé: J Pers Med
Pays: Switzerland
ID NLM: 101602269
Informations de publication
Date de publication:
16 Aug 2024
16 Aug 2024
Historique:
received:
09
07
2024
revised:
05
08
2024
accepted:
14
08
2024
medline:
31
8
2024
pubmed:
31
8
2024
entrez:
29
8
2024
Statut:
epublish
Résumé
RAD51C and RAD51D are crucial in homologous recombination (HR) DNA repair. The prevalence of the RAD51C and RAD51D mutations in breast cancer varies across ethnic groups. Associations of RAD51C and RAD51D germline pathogenic variants (GPVs) with breast and ovarian cancer predisposition have been recently reported and are of interest. We performed multi-gene panel sequencing to study the prevalence of RAD51C and RAD51D germline mutations among 3728 patients with hereditary breast and/or ovarian cancer (HBOC). We identified 18 pathogenic RAD51C and RAD51D mutation carriers, with a mutation frequency of 0.13% (5/3728) and 0.35% (13/3728), respectively. The most common recurrent mutation was RAD51D c.270_271dupTA; p.(Lys91Ilefs*13), with a mutation frequency of 0.30% (11/3728), which was also commonly identified in Asians. Only four out of six cases (66.7%) of this common mutation tested positive for homologous recombination deficiency (HRD). Taking the family studies in our registry and tumor molecular pathology together, we concluded that this relatively common RAD51D variant showed incomplete penetrance in our local Chinese community. Personalized genetic counseling emphasizing family history for families with this variant, as suggested at the UK Cancer Genetics Group (UKCGG) Consensus meeting, would also be appropriate in Chinese families.
Sections du résumé
BACKGROUND
BACKGROUND
RAD51C and RAD51D are crucial in homologous recombination (HR) DNA repair. The prevalence of the RAD51C and RAD51D mutations in breast cancer varies across ethnic groups. Associations of RAD51C and RAD51D germline pathogenic variants (GPVs) with breast and ovarian cancer predisposition have been recently reported and are of interest.
METHODS
METHODS
We performed multi-gene panel sequencing to study the prevalence of RAD51C and RAD51D germline mutations among 3728 patients with hereditary breast and/or ovarian cancer (HBOC).
RESULTS
RESULTS
We identified 18 pathogenic RAD51C and RAD51D mutation carriers, with a mutation frequency of 0.13% (5/3728) and 0.35% (13/3728), respectively. The most common recurrent mutation was RAD51D c.270_271dupTA; p.(Lys91Ilefs*13), with a mutation frequency of 0.30% (11/3728), which was also commonly identified in Asians. Only four out of six cases (66.7%) of this common mutation tested positive for homologous recombination deficiency (HRD).
CONCLUSIONS
CONCLUSIONS
Taking the family studies in our registry and tumor molecular pathology together, we concluded that this relatively common RAD51D variant showed incomplete penetrance in our local Chinese community. Personalized genetic counseling emphasizing family history for families with this variant, as suggested at the UK Cancer Genetics Group (UKCGG) Consensus meeting, would also be appropriate in Chinese families.
Identifiants
pubmed: 39202057
pii: jpm14080866
doi: 10.3390/jpm14080866
pmc: PMC11355318
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Dr. Ellen Li Charitable Foundation
ID : NA
Organisme : Kerry Kuok Foundation
ID : NA
Organisme : Health and Medical Research Fund
ID : 03143406
Organisme : Asian Fund for Cancer Research
ID : NA
Organisme : Hong Kong Hereditary Breast Cancer Family Registry
ID : NA
Références
Hered Cancer Clin Pract. 2019 Jan 18;17:3
pubmed: 30675318
J Cancer Res Clin Oncol. 2018 Dec;144(12):2495-2513
pubmed: 30306255
Hum Mutat. 2022 Mar;43(3):285-298
pubmed: 34923718
J Med Genet. 2012 Jul;49(7):429-32
pubmed: 22652533
Chin J Cancer Res. 2020 Aug;32(4):508-515
pubmed: 32963463
Clin Cancer Res. 2020 Jun 1;26(11):2487-2496
pubmed: 32086346
J Med Genet. 2023 May;60(5):417-429
pubmed: 36411032
BMC Cancer. 2018 Sep 26;18(1):926
pubmed: 30257646
Gynecol Oncol. 2012 Dec;127(3):552-5
pubmed: 22986143
Cancer Med. 2018 Apr;7(4):1349-1358
pubmed: 29522266
Cancer Res. 2017 Aug 15;77(16):4517-4529
pubmed: 28646019
Nat Commun. 2015 Dec 22;6:10086
pubmed: 26689913
Lancet. 2017 Oct 28;390(10106):1949-1961
pubmed: 28916367
Biomed Res Int. 2020 Sep 30;2020:2495157
pubmed: 33062672
Cancer Epidemiol Biomarkers Prev. 2021 Mar;30(3):469-473
pubmed: 33335023
J Natl Cancer Inst. 2018 Aug 1;110(8):855-862
pubmed: 30099541
Oncotarget. 2016 Mar 15;7(11):12537-53
pubmed: 26871286
Proc Natl Acad Sci U S A. 2001 Jul 17;98(15):8440-6
pubmed: 11459987
Nucleic Acids Res. 2006 Mar 06;34(5):1358-68
pubmed: 16522646
Breast Cancer Res Treat. 2019 Jul;176(1):165-170
pubmed: 30980208
Cancers (Basel). 2020 Aug 03;12(8):
pubmed: 32756499
Gynecol Oncol. 2017 Nov;147(2):375-380
pubmed: 28888541
J Natl Cancer Inst. 2020 Dec 14;112(12):1213-1221
pubmed: 32427313
PLoS One. 2017 Jun 7;12(6):e0178450
pubmed: 28591191
Nucleic Acids Res. 2002 Feb 15;30(4):1001-8
pubmed: 11842112
J Hum Genet. 2018 Nov;63(11):1149-1158
pubmed: 30111881
Breast Cancer Res Treat. 2020 Jun;181(2):465-473
pubmed: 32318955
Gynecol Oncol. 2016 Feb;140(2):221-5
pubmed: 26718727
Oncotarget. 2017 Nov 28;8(68):112258-112267
pubmed: 29348823
N Engl J Med. 2021 Feb 4;384(5):428-439
pubmed: 33471991
J Mol Diagn. 2020 Apr;22(4):544-554
pubmed: 32068069
Clin Cancer Res. 2014 Feb 1;20(3):764-75
pubmed: 24240112
Cancers (Basel). 2021 Aug 18;13(16):
pubmed: 34439310
Eur J Hum Genet. 2016 Nov;24(11):1591-1597
pubmed: 27273131
Ann Oncol. 2018 Oct 1;29(10):2046-2051
pubmed: 30165555
BMC Cancer. 2022 Dec 21;22(1):1337
pubmed: 36544182
Mol Genet Genomic Med. 2022 Jul;10(7):e1940
pubmed: 35608067
Genet Med. 2016 Aug;18(8):823-32
pubmed: 26681312
J Clin Oncol. 2016 May 1;34(13):1460-8
pubmed: 26976419
Eur J Hum Genet. 2017 Dec;25(12):1345-1353
pubmed: 29255180
J Natl Cancer Inst. 2021 Jul 1;113(7):884-892
pubmed: 33151324
Nucleic Acids Res. 2002 Feb 15;30(4):1009-15
pubmed: 11842113
Nat Cell Biol. 2009 May;11(5):592-603
pubmed: 19396164
Cancers (Basel). 2020 Sep 30;12(10):
pubmed: 33008098
Genesis. 2000 Mar;26(3):167-73
pubmed: 10705376
Mol Biol Rep. 2020 Jul;47(7):5315-5321
pubmed: 32601921
Int J Cancer. 2017 Jan 1;140(1):95-102
pubmed: 27616075
N Engl J Med. 2021 Feb 4;384(5):440-451
pubmed: 33471974
J Geriatr Oncol. 2020 Mar;11(2):316-319
pubmed: 31575519
PLoS Genet. 2019 Oct 4;15(10):e1008355
pubmed: 31584931
Hered Cancer Clin Pract. 2019 Jul 15;17:19
pubmed: 31341520
J Clin Oncol. 2015 Sep 10;33(26):2901-7
pubmed: 26261251
J Biol Chem. 2003 Jan 24;278(4):2469-78
pubmed: 12427746
Cell. 2004 Apr 30;117(3):337-47
pubmed: 15109494
Int J Mol Sci. 2023 Sep 23;24(19):
pubmed: 37833926
Genet Med. 2022 Jul;24(7):1468-1475
pubmed: 35396981
PLoS One. 2015 Jun 09;10(6):e0127711
pubmed: 26057125
Cancer Discov. 2017 Sep;7(9):984-998
pubmed: 28588062
Genes Dev. 2001 Dec 15;15(24):3308-18
pubmed: 11751636
Cancer Res Treat. 2018 Jul;50(3):917-925
pubmed: 29020732
Lancet Oncol. 2017 Jan;18(1):75-87
pubmed: 27908594
J Biol Chem. 2002 Mar 8;277(10):8406-11
pubmed: 11744692
Int J Cancer. 2014 May 1;134(9):2088-97
pubmed: 24130102
Eur J Med Genet. 2018 Jun;61(6):355-361
pubmed: 29409816
PLoS One. 2013;8(1):e54772
pubmed: 23372765
JAMA Oncol. 2016 Apr;2(4):482-90
pubmed: 26720728
Nat Genet. 2011 Aug 07;43(9):879-882
pubmed: 21822267
Semin Cancer Biol. 2019 Oct;58:29-46
pubmed: 30922960
Cancer Res Treat. 2022 Oct;54(4):1099-1110
pubmed: 34793666
Br J Cancer. 2012 Apr 10;106(8):1460-3
pubmed: 22415235
J Clin Oncol. 2015 Feb 1;33(4):304-11
pubmed: 25452441
J Ovarian Res. 2020 May 2;13(1):50
pubmed: 32359370
Nat Cancer. 2022 Oct;3(10):1181-1191
pubmed: 36253484
Int J Cancer. 2019 Nov 15;145(10):2692-2700
pubmed: 30927251
J Med Genet. 2020 Jan;57(1):53-61
pubmed: 31300551
J Natl Cancer Inst. 2020 Dec 14;112(12):1242-1250
pubmed: 32107557
J Med Genet. 2016 Jan;53(1):34-42
pubmed: 26534844
PLoS One. 2017 Oct 20;12(10):e0186043
pubmed: 29053726
Nucleic Acids Res. 2004 Jan 02;32(1):169-78
pubmed: 14704354
Genes Dev. 2001 Dec 15;15(24):3296-307
pubmed: 11751635
JCO Precis Oncol. 2018 Nov;2:1-4
pubmed: 35135167
Cancers (Basel). 2020 Oct 19;12(10):
pubmed: 33086730
N Engl J Med. 2016 Aug 4;375(5):443-53
pubmed: 27433846
Clin Cancer Res. 2017 Oct 15;23(20):6113-6119
pubmed: 28724667
Cancer Res. 2009 Feb 1;69(3):863-72
pubmed: 19155299
Int J Mol Sci. 2022 Jul 05;23(13):
pubmed: 35806485
Genes Chromosomes Cancer. 2021 May;60(5):373-384
pubmed: 33341987
Nucleic Acids Res. 2017 Feb 28;45(4):1835-1847
pubmed: 27924006